Precision Imaging for Kaposi Sarcoma (PRIME-KS) Device Feasibility Trial
This study is testing a new device called SkinScan3D camera. This camera takes detailed 3D images of Kaposi sarcoma (KS) lesions on the skin. The goal is to see how well the SkinScan3D camera can capture high-quality 3D images of these lesions. Researchers also want to see how quickly it can detect if a treatment is working or not. You may be able to join if you are at least 18 years old, have been diagnosed with KS, and have at least three KS lesions on your skin. You can be on or off treatment for your KS. The study is currently underway and aims to enroll 30 participants.
- Study design
- This is an observational study, meaning researchers will watch and record information without giving new treatments. It plans to include 30 participants.
- What's involved
- You would have a baseline visit and up to 12 additional visits over about 12 months. Each visit is expected to take around 30 minutes.
- Compensation
- Not stated in the trial record.
- Follow-up
- You would be followed for up to 12 months, with visits to assess image quality and treatment response.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Lee Ratner, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Rate of successful capture of high-quality 3D images of cutaneous KS lesionsBaseline and up to 12 additional visits, each visit will take approximately 30 minutes (estimated to be 12 months)
Feasibility is defined as \> 90% of lesions captured in the conventional imaging procedures are also seen in the SkinScan3D data, and that unique height and volume data is captured by the SkinScan3D for \> 70% of lesions.
- Time to detect response or failure to treatment (Cohort B only)Baseline and up to 12 additional visits, each visit will take approximately 30 minutes (estimated to be 12 months)
Differences between the SkinScan3D and standard 2D in time to detect response or failure to treatment.